Breast regimen-specific consent forms

Dear All,

 

I am pleased to inform you that the breast regimen-specific consent forms have been updated with the following:

  • Subcutaneous administration option for regimens containing Trastuzumab  and Pertuzumab.
  • Standard  statement on alcohol to regimens containing Gemcitabine and Paclitaxel.
  • Standard statement indicating the risk of diabetes with SACT treatment, including those where steroids are in the protocol for anti-emetic/allergy.

The forms are available via CRUK website at: www.cruk.org/sact_consent.

Please forward to your colleagues.

Any questions please let me know.

 

Best wishes,

Alia

Alia Nizam |Specialist Oncology Pharmacist. CRUK – Information Lead|

Guy’s and St Thomas’ NHS Foundation Trust

Guy’s Hospital | Great Maze Pond | London | SE1 9RT
SACT regimen-specific consent forms: www.cruk.org/sact consent |

Our values: Put patients first | Take pride in what we do | Respect others | Strive to be the best | Act with integrity

 

Latest News

By Suriya Marshall on 14th March 2026

Parliamentary Intervention Sparks National Campaign to Protect NHS Staff from Hazardous Medicinal Products (HMPs)

First UK Campaign to Protect Healthcare Workers from Exposure to Hazardous Medicinal Products (HMPs) launches in Westminster London, 10 March 2026: Today, the Safer Healthcare and Biosafety Network (SHBN) launches…

Read article
By Suriya Marshall on 14th March 2026

Clinical Pharmacy Congress. 8th-9th May 2026

Dear BOPA member, We are excited to announce that we have partnered with Clinical Pharmacy Congress 2026. Clinical Pharmacy Congress is the UK’s leading event for clinical pharmacy professionals working across…

Read article
By BOPA Executive Committee on 13th March 2026

First UK Campaign to Protect Healthcare Workers from Exposure to Hazardous Medicinal Products (HMPs) launches in Westminster

London, 10 March 2026: The Safer Healthcare and Biosafety Network (SHBN) launches a new campaign titled “Protecting Healthcare Workers: Safer Handling of Hazardous Medicinal Products” to raise awareness of the dangers…

Read article
By BOPA on 13th March 2026

Invitation to Participate: SWEET-PLUS Study

You are invited to take part in a research study called SWEET-PLUS (NIHR Research for Patient Benefit: 207952), run by Newcastle and Oxford Brookes Universities. SWEET-PLUS aims to understand experiences…

Read article